Overview

Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

This is a blinded, placebo-controlled, randomised controlled trial looking at the effects of Heme arginate (HA) on cadaveric renal transplantation. The investigators know that HA can upregulate HO-1, which has been shown to have a protective effect on animal transplants. The investigators will be giving HA/placebo to participants prior to transplant and repeat again on day 2 post-transplant and compare outcomes.

Phase:

Phase 3

Details

Lead Sponsor:

University of Edinburgh

Collaborator:

NHS Lothian